Exton’s Absorption Systems has been issued a U.S. patent for its groundbreaking In Vitro Dissolution Absorption System (IDAS) technology, which evaluates drug dissolution and absorption in a variety of dosage formats, including tablets, capsules, and pre-formulations.
The company, which is a global leader in the science of translational medicine, said that industry demand for IDAS2 is already high due to its innovative design. The new technique enables pharmaceutical scientists to evaluate the two fundamental properties of drug products by simultaneously monitoring their dissolution rate and absorption rate.
IDAS2 will also improve reliability of pre-clinical formulation testing, thanks to its ability to rapidly screen pre-formulations together with finished oral dosage forms for both dissolution and permeability, simultaneously in an in-vitro format. This will lead to better decisions concerning formulations that will then advance to clinical testing in humans.
“It’s very rewarding to see our efforts come to fruition in this way and to know that this technology will help get more effective and safer drugs to patients sooner,” said Dr. Jibin Li, co-inventor on the patent with Dr. Ismael J. Hidalgo.
Check out previous VISTA Today coverage of Absorption Systems here.
